Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

16.70USD
23 Apr 2018
Change (% chg)

$-0.60 (-3.47%)
Prev Close
$17.30
Open
$17.30
Day's High
$17.40
Day's Low
$16.55
Volume
46,917
Avg. Vol
90,497
52-wk High
$18.75
52-wk Low
$7.30

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.44 -- --
ROI: -65.15 1.58 14.38
ROE: -65.34 2.41 16.07

BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares

* STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​ Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)

16 Mar 2018

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

16 Mar 2018

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

22 Jan 2018

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

31 Oct 2017

Competitors

Earnings vs. Estimates